PTC Therapeutics, Inc. (PTCT) CEO Stuart Walter Peltz Sells 2,230 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Stuart Walter Peltz sold 2,230 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $18.03, for a total transaction of $40,206.90. Following the transaction, the chief executive officer now directly owns 26,646 shares in the company, valued at $480,427.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) traded down $1.80 during trading hours on Tuesday, hitting $21.49. 1,460,000 shares of the company were exchanged, compared to its average volume of 878,114. The company has a quick ratio of 2.97, a current ratio of 3.08 and a debt-to-equity ratio of 0.98. The stock has a market cap of $891.61, a P/E ratio of -7.44 and a beta of 1.23. PTC Therapeutics, Inc. has a 52 week low of $8.12 and a 52 week high of $23.71.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.67) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.01). PTC Therapeutics had a negative return on equity of 75.19% and a negative net margin of 75.64%. analysts predict that PTC Therapeutics, Inc. will post -2.01 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP lifted its holdings in PTC Therapeutics by 5.8% during the third quarter. RTW Investments LP now owns 3,495,143 shares of the biopharmaceutical company’s stock valued at $69,938,000 after purchasing an additional 190,929 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of PTC Therapeutics by 17.2% in the second quarter. Vanguard Group Inc. now owns 2,366,564 shares of the biopharmaceutical company’s stock worth $43,379,000 after buying an additional 346,525 shares in the last quarter. FMR LLC lifted its holdings in shares of PTC Therapeutics by 4.1% in the second quarter. FMR LLC now owns 703,973 shares of the biopharmaceutical company’s stock worth $12,904,000 after buying an additional 27,500 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of PTC Therapeutics by 8.5% in the second quarter. Northern Trust Corp now owns 615,096 shares of the biopharmaceutical company’s stock worth $11,275,000 after buying an additional 48,308 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of PTC Therapeutics by 1.1% in the second quarter. Dimensional Fund Advisors LP now owns 528,586 shares of the biopharmaceutical company’s stock worth $9,689,000 after buying an additional 5,960 shares in the last quarter. 86.12% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. JPMorgan Chase & Co. lifted their target price on shares of PTC Therapeutics to $15.00 and gave the stock a “neutral” rating in a research report on Friday, November 24th. Bank of America downgraded shares of PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Thursday, October 26th. ValuEngine upgraded shares of PTC Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Cowen restated a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $19.14.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/ptc-therapeutics-inc-ptct-ceo-stuart-walter-peltz-sells-2230-shares/1821383.html.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.